- 執筆（按單位拼音和姓氏筆畫排列，排名不分先后）李沁芮、楊志仙、秦炯（北京大學人民醫院）、胡越（重慶醫科大學附屬兒童醫院）、陶哲[大連市婦女兒童醫療中心（集團）]、周水珍（復旦大學附屬兒科醫院）、朱國行（復旦大學附屬華山醫院）、林衛紅（吉林大學第一醫院）、楊光（解放軍總醫院第一醫學中心）、劉仕勇（陸軍軍醫大學新橋醫院）、李保敏（山東大學齊魯醫院）、何大可（上海交通大學醫學院附屬新華醫院）、趙霞（深圳市兒童醫院）、梁樹立（首都醫科大學附屬北京兒童醫院）、王群（首都醫科大學附屬北京天壇醫院）、王夢陽（首都醫科大學三博腦科醫院）、周東（四川大學華西醫院）、李巖（蘇州大學附屬兒童醫院）、張玉琴（天津市兒童醫院）、孫丹（武漢兒童醫院）、高峰（浙江大學醫學院附屬兒童醫院）、禚志紅（鄭州大學第一附屬醫院）、盧強（中國醫學科學院北京協和醫院）;
中國抗癲癇協會結節性硬化癥與罕見病專業委員會,
Email: zhixian.yang@163.com
Citation： 中國抗癲癇協會結節性硬化癥與罕見病專業委員會. 唑尼沙胺治療癲癇及相關疾病中國專家共識（2026版）. Journal of Epilepsy, 2026, 12(5): 376-390. doi: 10.7507/2096-0247.202606005 Copy
Copyright ? the editorial department of Journal of Epilepsy of West China Medical Publisher. All rights reserved
| 1. | Li S, Wang Y, Wang W, et al. The national comprehensive governance for epilepsy prevention and control in china[J]. Epilepsia Open, 2022, 7(1): 27-35. |
| 2. | Uno H, Kurokawa M, Masuda Y, et al. Studies on 3-substituted 1, 2-benzisoxazole derivatives. 6. Syntheses of 3-(sulfamoylmethyl)-1, 2-benzisoxazole derivatives and their anticonvulsant activities [J]. Journal of Medicinal Chemistry, 1979, 22(2): 180-183. |
| 3. | Gidal BE, Resnick T, Smith MC, et al. Zonisamide: a comprehensive, updated review for the clinician[J]. Neurology Clinical Practice, 2024, 14(1): e200210. |
| 4. | Panda PK, Sharawat IK, Panda P, et al. Efficacy, tolerability, and safety of zonisamide in children with epileptic spasms: a systematic review and meta-analysis[J]. Seizure, 2021, 91: 374-383. |
| 5. | Strzelczyk A, Schubert-Bast S. Expanding the treatment landscape for lennox-gastaut syndrome: current and future strategies[J]. CNS Drugs, 2021, 35(1): 61-83. |
| 6. | Kadian R, Patel P, Kumar A. Zonisamide [Z]. StatPearls, 2025. |
| 7. | Assarzadegan F, Tabesh H, Hosseini-Zijoud SM, et al. Comparing zonisamide with sodium valproate in the management of migraine headaches: double-blind randomized clinical trial of efficacy and safety[J]. Iranian Red Crescent Medical Journal, 2016, 18(9): e23768. |
| 8. | Drake ME, Greathouse NI, Renner JB, et al. Open-label zonisamide for refractory migraine[J]. Clinical Neuropharmacology, 2004, 27(6): 278-280. |
| 9. | Xia G, Han Y, Meng F, et al. Reciprocal control of obesity and anxiety-depressive disorder via a GABA and serotonin neural circuit[J]. Molecular Psychiatry, 2021, 26(7): 2837-2853. |
| 10. | Gadde KM, Franciscy DM, Wagner HR, et al. Zonisamide for weight loss in obese adults: a randomized controlled trial[J]. Journal of the American Medical Association, 2003, 289(14): 1820-1825. |
| 11. | Jing XZ, Yuan XZ, Luo X, et al. An update on nondopaminergic treatments for motor and non-motor symptoms of parkinson's disease[J]. Current Neuropharmacology, 2023, 21(8): 1806-1826. |
| 12. | Li C, Xue L, Liu Y, et al. Zonisamide for the treatment of parkinson disease: a current update[J]. Frontiers in Neuroscience, 2020, 14: 574652. |
| 13. | 中華醫學會神經病學分會, 中華醫學會神經病學分會腦電圖與癲癇學組. 抗癲癇發作藥物聯合使用中國專家共識[J]. 中華神經科雜志, 2024, 57(2): 108-117.Chinese Society of Neurology, Chinese Medical Association; EEG and Epilepsy Group, Chinese Society of Neurology, Chinese Medical Association. Chinese expert consensus on combined use of anti-seizure medications[J]. Chinese Journal of Neurology, 2024, 57(2): 108-117. |
| 14. | Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs[J]. The Lancet Neurology, 2003, 2(8): 473-481. |
| 15. | Food and Drug Administration. ZONEGRAN? (zonisamide) capsules description [Z], 2020. |
| 16. | National Institute for Health and Care Excellence. Epilepsies in children, young people and adults [Z], 2025. |
| 17. | Kanner AM, Ashman E, Gloss D, et al. Practice guideline update summary: efficacy and tolerability of the new antiepileptic drugs i: treatment of new-onset epilepsy: report of the american epilepsy society and the guideline development, dissemination, and implementation subcommittee of the american academy of neurology[J]. Epilepsy Currents, 2018, 18(4): 260-268. |
| 18. | Glauser T, Ben-Menachem E, Bourgeois B, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes[J]. Epilepsia, 2013, 54(3): 551-563. |
| 19. | 中華醫學會神經病學分會, 中華醫學會神經病學分會腦電圖與癲癇學組. 中國成人局灶性癲癇規范化診治指南[J]. 中華神經科雜志, 2022, 55(12): 1341-1352.Chinese Society of Neurology, Chinese Medical Association; EEG and Epilepsy Group, Chinese Society of Neurology, Chinese Medical Association. Chinese guidelines for standardized diagnosis and treatment of focal epilepsy in adults[J]. Chinese Journal of Neurology, 2022, 55(12): 1341-1352. |
| 20. | Brigo F, Lattanzi S, Igwe SC, et al. Zonisamide add-on therapy for focal epilepsy[J]. Cochrane Database of Systematic Reviews, 2020, 7: CD001416. |
| 21. | Deng NJ, Li XY, Zhang ZX, et al. Effectiveness and safety of single anti-seizure medication as adjunctive therapy for drug-resistant focal epilepsy based on network meta-analysis[J]. Frontiers in Pharmacology, 2025, 16: 1500475. |
| 22. | Brodie MJ, Duncan R, Vespignani H, et al. Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures[J]. Epilepsia, 2005, 46(1): 31-41. |
| 23. | Lu Y, Xiao Z, Yu W, et al. Efficacy and safety of adjunctive zonisamide in adult patients with refractory partial-onset epilepsy: a randomized, double-blind, placebo-controlled trial[J]. Clinical Drug Investigation, 2011, 31(4): 221-229. |
| 24. | Yagi K. Overview of japanese experience-controlled and uncontrolled trials [J]. Seizure, 2004, 13(Suppl 1): S11-15. |
| 25. | Yamauchi T, Aikawa H. Efficacy of zonisamide: our experience [J]. Seizure, 2004, 13(Suppl 1): S41-S48. |
| 26. | 中華醫學會神經病學分會. 新診斷癲癇初始抗癲癇發作藥物治療指南[J]. 中華神經科雜志, 2025, 58(11): 1137-1151.Chinese Society of Neurology, Chinese Medical Association. Guidelines for initial anti-seizure medication therapy in newly diagnosed epilepsy[J]. Chinese Journal of Neurology, 2025, 58(11): 1137-1151. |
| 27. | Baulac M, Brodie MJ, Patten A, et al. Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, non-inferiority trial[J]. The Lancet Neurology, 2012, 11(7): 579-588. |
| 28. | Ohtahara S. Zonisamide in the management of epilepsy-Japanese experience [J]. Epilepsy Research, 2006, 68(Suppl 2): S25-S33. |
| 29. | 中華醫學會兒科學分會神經學組. 新診斷兒童癲癇的初始單藥治療專家共識[J]. 中華兒科雜志, 2015, 53(10): 734-737.Neurology Group, Chinese Society of Pediatrics, Chinese Medical Association. Expert consensus on initial monotherapy in newly diagnosed childhood epilepsy[J]. Chinese Journal of Pediatrics, 2015, 53(10): 734-737. |
| 30. | Liu P, Zhang L, Zeng Q, et al. Efficacy and safety of zonisamide addition in children with developmental epileptic encephalopathy/epileptic encephalopathy: a real-world study[J]. CNS Neuroscience & Therapeutics, 2026, 32(4): e70865. |
| 31. | Wang S, Sun H, Wang Z, et al. Adjunctive treatment for pediatric focal epilepsy: a systematic review[J]. European Journal of Clinical Pharmacology, 2025, 81(4): 507-523. |
| 32. | Guerrini R, Rosati A, Segieth J, et al. A randomized phase iii trial of adjunctive zonisamide in pediatric patients with partial epilepsy[J]. Epilepsia, 2013, 54(8): 1473-1480. |
| 33. | Guerrini R, Rosati A, Bradshaw K, et al. Adjunctive zonisamide therapy in the long-term treatment of children with partial epilepsy: results of an open-label extension study of a phase III, randomized, double-blind, placebo-controlled trial[J]. Epilepsia, 2014, 55(4): 568-578. |
| 34. | Marson A, Burnside G, Appleton R, et al. The SANAD ii study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial[J]. The Lancet, 2021, 397(10282): 1363-1374. |
| 35. | 住友制藥株式會社. 唑尼沙胺片/散說明書 [Z], 2025.Sumitomo Pharmaceuticals Co. , Ltd. Instructions for Zonisamide Tablets/Powder [Z], 2025. |
| 36. | 中國抗癲癇協會. 臨床診療指南: 2023修訂版. 癲癇病分冊 [M]. 北京: 人民衛生出版社, 2023.China Association Against Epilepsy. Clinical practice guidelines (2023 revised edition): volume of epilepsy [M]. Beijing: People's Medical Publishing House, 2023. |
| 37. | Biton V. Clinical pharmacology and mechanism of action of zonisamide[J]. Clinical Neuropharmacology, 2007, 30(4): 230-240. |
| 38. | Wilfong A, Schultz R. Zonisamide for absence seizures[J]. Epilepsy Research, 2005, 64(1-2): 31-34. |
| 39. | Seki T, Kumagai N, Maezawa M. Effects of zonisamide monotherapy in children with epilepsy [J]. Seizure, 2004, 13(Suppl 1): S26-32. |
| 40. | Kothare SV, Valencia I, Khurana DS, et al. Efficacy and tolerability of zonisamide in juvenile myoclonic epilepsy[J]. Epileptic Disorders, 2004, 6(4): 267-270. |
| 41. | Velizarova R, Crespel A, Genton P, et al. Zonisamide for refractory juvenile absence epilepsy[J]. Epilepsy Research, 2014, 108(7): 1263-1266. |
| 42. | 北京協和醫院罕見病多學科協作組, 中國罕見病聯盟. 氯巴占治療難治性癲癇專家共識[J]. 協和醫學雜志, 2022, 13(5): 768-782.Multidisciplinary Team for Rare Diseases, Peking Union Medical College Hospital; China Rare Disease League. Expert consensus on clobazam for the treatment of refractory epilepsy[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(5): 768-782. |
| 43. | 中國抗癲癇協會創新與轉化專委會. Lennox-gastaut綜合征診斷治療的中國專家共識[J]. 癲癇雜志, 2022, 8(3): 187-195.Special Committee on Innovation and Translation, China Association Against Epilepsy. Chinese expert consensus on the diagnosis and treatment of Lennox-Gastaut Syndrome[J]. Journal of Epilepsy, 2022, 8(3): 187-195. |
| 44. | You SJ, Kang HC, Kim HD, et al. Clinical efficacy of zonisamide in lennox-gastaut syndrome: korean multicentric experience[J]. Brain & Development, 2008, 30(4): 287-290. |
| 45. | Lee YJ, Kang HC, Seo JH, et al. Efficacy and tolerability of adjunctive therapy with zonisamide in childhood intractable epilepsy[J]. Brain & Development, 2010, 32(3): 208-212. |
| 46. | 中國抗癲癇協會創新與轉化專業委員會, 中華醫學會兒科學分會罕見病學組, 中華醫學會兒科學分會神經學組. Dravet綜合征診斷與治療的中國專家共識[J]. 癲癇雜志, 2024, 10(1): 356-365.Special Committee on Innovation and Translation, China Association Against Epilepsy; Rare Diseases Group, Chinese Society of Pediatrics, Chinese Medical Association; Neurology Group, Chinese Society of Pediatrics, Chinese Medical Association. Chinese expert consensus on the diagnosis and treatment of Dravet Syndrome[J]. Journal of Epilepsy, 2024, 10(1): 356-365. |
| 47. | Wirrell EC, Laux L, Donner E, et al. Optimizing the diagnosis and management of dravet syndrome: recommendations from a north American consensus panel[J]. Pediatric Neurology, 2017, 68: 18-34. |
| 48. | Tanabe T, Awaya Y, Matsuishi T, et al. Management of and prophylaxis against status epilepticus in children with severe myoclonic epilepsy in infancy (SMEI; dravet syndrome)--a nationwide questionnaire survey in Japan [J]. Brain & Development, 2008, 30(10): 629-635. |
| 49. | Zuberi SM, Wirrell E, Yozawitz E, et al. ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: position statement by the ILAE task force on nosology and definitions[J]. Epilepsia, 2022, 63(6): 1349-1397. |
| 50. | Sharma S, Kaushik JS, Srivastava K, et al. Association of child neurology (AOCN) - indian epilepsy society (IES) consensus guidelines for the diagnosis and management of west syndrome[J]. Indian Pediatrics, 2021, 58(1): 54-66. |
| 51. | Ramantani G, Bolsterli BK, Alber M, et al. Treatment of infantile spasm syndrome: update from the interdisciplinary guideline committee coordinated by the german-speaking society of neuropediatrics[J]. Neuropediatrics, 2022, 53(6): 389-401. |
| 52. | Aslan M, Gungor S. Effectiveness of zonisamide in childhood refractory epilepsy[J]. Child's Nervous System, 2022, 38(5): 971-976. |
| 53. | Melikishvili G, Epitashvili N, Tabatadze N, et al. New insights in phenomenology and treatment of epilepsy in CDKL5 encephalopathy[J]. Epilepsy & Behavior, 2019, 94: 308-311. |
| 54. | Muller A, Helbig I, Jansen C, et al. Retrospective evaluation of low long-term efficacy of antiepileptic drugs and ketogenic diet in 39 patients with CDKL5-related epilepsy[J]. European Journal of Paediatric Neurology, 2016, 20(1): 147-151. |
| 55. | Ren Y, Hu W, Su S, et al. Recent advances of epilepsy associated with neurofibromatosis type 1[J]. Frontiers in Neurology, 2025, 16: 1640309. |
| 56. | Fanella M, Morano A, Cerulli Irelli E, et al. Idiopathic generalized epilepsy and café-au-lait macules as the predominant features in NF1 mild form[J]. Journal of Translational Genetics and Genomics, 2021, 5: 124-129. |
| 57. | Crino A, Fintini D, Bocchini S, et al. Obesity management in prader-willi syndrome: current perspectives[J]. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2018, 11: 579-593. |
| 58. | McElroy SL, Kotwal R, Guerdjikova AI, et al. Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial[J]. Journal of Clinical Psychiatry, 2006, 67(12): 1897-1906. |
| 59. | Gadde KM, Kopping MF, Wagner HR, et al. Zonisamide for weight reduction in obese adults: a 1-year randomized controlled trial[J]. Archives of Internal Medicine, 2012, 172(20): 1557-1564. |
| 60. | Whittington J, Holland A. A review of psychiatric conceptions of mental and behavioural disorders in prader-willi syndrome[J]. Neuroscience & Biobehavioral Reviews, 2018, 95: 396-405. |
| 61. | Yang LP, Perry CM. Zonisamide: in parkinson's disease[J]. CNS Drugs, 2009, 23(8): 703-711. |
| 62. | Matsunaga S, Kishi T, Iwata N. Combination therapy with zonisamide and antiparkinson drugs for parkinson's disease: a meta-analysis[J]. Journal of Alzheimer's Disease, 2017, 56(4): 1229-1239. |
| 63. | Aboulatta L, Haidar L, Abou-Setta A, et al. Efficacy and safety of MAO-B inhibitors safinamide and zonisamide in parkinson's disease: a systematic review and meta-analysis of randomized controlled trials[J]. CNS Drugs, 2023, 37(11): 941-956. |
| 64. | Essam M, Hamid E, Abushady E, et al. Role of zonisamide in advanced parkinson's disease: a randomized placebo-controlled study[J]. Neurological Sciences, 2024, 45(4): 1725-1734. |
| 65. | Chu CS, Yang FC, Tseng PT, et al. Treatment efficacy and acceptability of pharmacotherapies for dementia with lewy bodies: a systematic review and network meta-analysis[J]. Archives of Gerontology and Geriatrics, 2021, 96: 104474. |
| 66. | Odawara T, Hasegawa K, Kajiwara R, et al. Long-term efficacy and safety of zonisamide for treatment of parkinsonism in patients with dementia with lewy bodies: an open-label extension of a phase three randomized controlled tria [J]l. The American Journal of Geriatric Psychiatry, 2022, 30(3): 314-328. |
| 67. | Hasegawa K, Kochi K, Maruyama H, et al. Efficacy and safety of zonisamide in dementia with lewy bodies patients with parkinsonism: a post hoc analysis of two randomized, double-blind, placebo-controlled trials[J]. Journal of Alzheimer's Disease, 2021, 79(2): 627-637. |
| 68. | Zesiewicz TA, Ward CL, Hauser RA, et al. A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor[J]. Movement Disorders, 2007, 22(2): 279-282. |
| 69. | Morita S, Miwa H, Kondo T. Effect of zonisamide on essential tremor: a pilot crossover study in comparison with arotinolol[J]. Parkinsonism & Related Disorders, 2005, 11(2): 101-103. |
| 70. | Ondo WG. Zonisamide for essential tremor[J]. Clinical Neuropharmacology, 2007, 30(6): 345-349. |
| 71. | Pan XF, Fang ZZ, Zhang L, et al. Obesity in china: current progress and future prospects[J]. The Lancet Diabetes & Endocrinology, 2026, 14(2): 178-186. |
| 72. | Ben-Menachem E. Weight issues for people with epilepsy--a review [J]. Epilepsia, 2007, 48(Suppl 9): 42-45. |
| 73. | Ottman R, Lipton RB. Comorbidity of migraine and epilepsy[J]. Neurology, 1994, 44(11): 2105-2110. |
| 74. | Pappagallo M. Newer antiepileptic drugs: possible uses in the treatment of neuropathic pain and migraine[J]. Clinical Therapeutics, 2003, 25(10): 2506-2538. |
| 75. | Kochak GM, Page JG, Buchanan RA, et al. Steady-state pharmacokinetics of zonisamide, an antiepileptic agent for treatment of refractory complex partial seizures[J]. Journal of Clinical Pharmacology, 1998, 38(2): 166-171. |
| 76. | Mohammadianinejad SE, Abbasi V, Sajedi SA, et al. Zonisamide versus topiramate in migraine prophylaxis: a double-blind randomized clinical trial[J]. Clinical Neuropharmacology, 2011, 34(4): 174-177. |
| 77. | Villani V, Ciuffoli A, Prosperini L, et al. Zonisamide for migraine prophylaxis in topiramate-intolerant patients: an observational study[J]. Headache, 2011, 51(2): 287-291. |
| 78. | 中國抗癲癇協會共患病專業委員會. 癲癇共患偏頭痛診斷治療的中國專家共識[J]. 癲癇雜志, 2019, 5(5): 327-332.Special Committee on Comorbidities, China Association Against Epilepsy. Chinese expert consensus on diagnosis and treatment of epilepsy comorbid with migraine[J]. Journal of Epilepsy, 2019, 5(5): 327-332. |
| 79. | Berry-Noronha A, Manoleehakul P, Rottler A, et al. Risk of adverse pregnancy outcomes associated with antiseizure medications and their indications: a systematic review and meta-analysis[J]. Neurology, 2025, 104(3): e210233. |
| 80. | Weston J, Bromley R, Jackson CF, et al. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child[J]. Cochrane Database of Systematic Reviews, 2016, 11: CD010224. |
| 81. | Straub L, Hernandez-Diaz S, Bateman BT, et al. Prenatal antiseizure drug exposure and risk of neurodevelopmental disorders in children: population based cohort study[J]. British Medical Journal, 2026, 392: e085725. |
| 82. | Cross JH, Auvin S, Patten A, et al. Safety and tolerability of zonisamide in paediatric patients with epilepsy[J]. European Journal of Paediatric Neurology, 2014, 18(6): 747-758. |
| 83. | Low PA, James S, Peschel T, et al. Zonisamide and associated oligohidrosis and hyperthermia[J]. Epilepsy Research, 2004, 62(1): 27-34. |
| 84. | Knudsen JF, Thambi LR, Kapcala LP, et al. Oligohydrosis and fever in pediatric patients treated with zonisamide[J]. Pediatric Neurology, 2003, 28(3): 184-189. |
| 85. | Horiuchi K, Kudo A, Nakamura S, et al. Switching from zonisamide to perampanel improved the frequency of seizures caused by hyperthermia in dravet syndrome: a case report[J]. Journal of Medical Case Reports, 2024, 18(1): 3. |
| 86. | Elan Pharmaceuticals. Zonegran (zonisamide) package insert [Z], 2009. |
| 87. | Mula M. Topiramate and cognitive impairment: evidence and clinical implications[J]. Therapeutic Advances in Drug Safety, 2012, 3(6): 279-289. |
| 88. | Wandschneider B, Burdett J, Townsend L, et al. Effect of topiramate and zonisamide on fMRI cognitive networks[J]. Neurology, 2017, 88(12): 1165-1171. |
| 89. | Eun SH, Kim HD, Eun BL, et al. Comparative trial of low- and high-dose zonisamide as monotherapy for childhood epilepsy[J]. Seizure, 2011, 20(7): 558-563. |
| 90. | Park SP, Hwang YH, Lee HW, et al. Long-term cognitive and mood effects of zonisamide monotherapy in epilepsy patients[J]. Epilepsy & Behavior, 2008, 12(1): 102-108. |
| 91. | Dauphinais D, Knable M, Rosenthal J, et al. Zonisamide for bipolar depression: a randomized, double blind, placebo-controlled, adjunctive trial[J]. Psychopharmacology Bulletin, 2011, 44(2): 73-84. |
| 92. | Anand A, Bukhari L, Jennings SA, et al. A preliminary open-label study of zonisamide treatment for bipolar depression in 10 patients[J]. Journal of Clinical Psychiatry, 2005, 66(2): 195-198. |
| 93. | McElroy SL, Suppes T, Keck PE, et al. Open-label adjunctive zonisamide in the treatment of bipolar disorders: a prospective trial[J]. Journal of Clinical Psychiatry, 2005, 66(5): 617-624. |
| 94. | Cavanna AE, Seri S. Psychiatric adverse effects of zonisamide in patients with epilepsy and mental disorder comorbidities[J]. Epilepsy & Behavior, 2013, 29(2): 281-284. |
| 95. | Wu CB, Yao PS, Su LC, et al. Two cases of psychiatric symptoms associated with zonisamide antiepileptic treatment[J]. Clinical Psychopharmacology and Neuroscience, 2026, 24(1): 202-206. |
| 96. | Boycott KM, Rath A, Chong JX, et al. International cooperation to enable the diagnosis of all rare genetic diseases[J]. American Journal of Human Genetics, 2017, 100(5): 695-705. |
| 97. | Wroe S. Zonisamide and renal calculi in patients with epilepsy: how big an issue? [J] Current Medical Research and Opinion, 2007, 23(8): 1765-1773. |
- 1. Li S, Wang Y, Wang W, et al. The national comprehensive governance for epilepsy prevention and control in china[J]. Epilepsia Open, 2022, 7(1): 27-35.
- 2. Uno H, Kurokawa M, Masuda Y, et al. Studies on 3-substituted 1, 2-benzisoxazole derivatives. 6. Syntheses of 3-(sulfamoylmethyl)-1, 2-benzisoxazole derivatives and their anticonvulsant activities [J]. Journal of Medicinal Chemistry, 1979, 22(2): 180-183.
- 3. Gidal BE, Resnick T, Smith MC, et al. Zonisamide: a comprehensive, updated review for the clinician[J]. Neurology Clinical Practice, 2024, 14(1): e200210.
- 4. Panda PK, Sharawat IK, Panda P, et al. Efficacy, tolerability, and safety of zonisamide in children with epileptic spasms: a systematic review and meta-analysis[J]. Seizure, 2021, 91: 374-383.
- 5. Strzelczyk A, Schubert-Bast S. Expanding the treatment landscape for lennox-gastaut syndrome: current and future strategies[J]. CNS Drugs, 2021, 35(1): 61-83.
- 6. Kadian R, Patel P, Kumar A. Zonisamide [Z]. StatPearls, 2025.
- 7. Assarzadegan F, Tabesh H, Hosseini-Zijoud SM, et al. Comparing zonisamide with sodium valproate in the management of migraine headaches: double-blind randomized clinical trial of efficacy and safety[J]. Iranian Red Crescent Medical Journal, 2016, 18(9): e23768.
- 8. Drake ME, Greathouse NI, Renner JB, et al. Open-label zonisamide for refractory migraine[J]. Clinical Neuropharmacology, 2004, 27(6): 278-280.
- 9. Xia G, Han Y, Meng F, et al. Reciprocal control of obesity and anxiety-depressive disorder via a GABA and serotonin neural circuit[J]. Molecular Psychiatry, 2021, 26(7): 2837-2853.
- 10. Gadde KM, Franciscy DM, Wagner HR, et al. Zonisamide for weight loss in obese adults: a randomized controlled trial[J]. Journal of the American Medical Association, 2003, 289(14): 1820-1825.
- 11. Jing XZ, Yuan XZ, Luo X, et al. An update on nondopaminergic treatments for motor and non-motor symptoms of parkinson's disease[J]. Current Neuropharmacology, 2023, 21(8): 1806-1826.
- 12. Li C, Xue L, Liu Y, et al. Zonisamide for the treatment of parkinson disease: a current update[J]. Frontiers in Neuroscience, 2020, 14: 574652.
- 13. 中華醫學會神經病學分會, 中華醫學會神經病學分會腦電圖與癲癇學組. 抗癲癇發作藥物聯合使用中國專家共識[J]. 中華神經科雜志, 2024, 57(2): 108-117.Chinese Society of Neurology, Chinese Medical Association; EEG and Epilepsy Group, Chinese Society of Neurology, Chinese Medical Association. Chinese expert consensus on combined use of anti-seizure medications[J]. Chinese Journal of Neurology, 2024, 57(2): 108-117.
- 14. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs[J]. The Lancet Neurology, 2003, 2(8): 473-481.
- 15. Food and Drug Administration. ZONEGRAN? (zonisamide) capsules description [Z], 2020.
- 16. National Institute for Health and Care Excellence. Epilepsies in children, young people and adults [Z], 2025.
- 17. Kanner AM, Ashman E, Gloss D, et al. Practice guideline update summary: efficacy and tolerability of the new antiepileptic drugs i: treatment of new-onset epilepsy: report of the american epilepsy society and the guideline development, dissemination, and implementation subcommittee of the american academy of neurology[J]. Epilepsy Currents, 2018, 18(4): 260-268.
- 18. Glauser T, Ben-Menachem E, Bourgeois B, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes[J]. Epilepsia, 2013, 54(3): 551-563.
- 19. 中華醫學會神經病學分會, 中華醫學會神經病學分會腦電圖與癲癇學組. 中國成人局灶性癲癇規范化診治指南[J]. 中華神經科雜志, 2022, 55(12): 1341-1352.Chinese Society of Neurology, Chinese Medical Association; EEG and Epilepsy Group, Chinese Society of Neurology, Chinese Medical Association. Chinese guidelines for standardized diagnosis and treatment of focal epilepsy in adults[J]. Chinese Journal of Neurology, 2022, 55(12): 1341-1352.
- 20. Brigo F, Lattanzi S, Igwe SC, et al. Zonisamide add-on therapy for focal epilepsy[J]. Cochrane Database of Systematic Reviews, 2020, 7: CD001416.
- 21. Deng NJ, Li XY, Zhang ZX, et al. Effectiveness and safety of single anti-seizure medication as adjunctive therapy for drug-resistant focal epilepsy based on network meta-analysis[J]. Frontiers in Pharmacology, 2025, 16: 1500475.
- 22. Brodie MJ, Duncan R, Vespignani H, et al. Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures[J]. Epilepsia, 2005, 46(1): 31-41.
- 23. Lu Y, Xiao Z, Yu W, et al. Efficacy and safety of adjunctive zonisamide in adult patients with refractory partial-onset epilepsy: a randomized, double-blind, placebo-controlled trial[J]. Clinical Drug Investigation, 2011, 31(4): 221-229.
- 24. Yagi K. Overview of japanese experience-controlled and uncontrolled trials [J]. Seizure, 2004, 13(Suppl 1): S11-15.
- 25. Yamauchi T, Aikawa H. Efficacy of zonisamide: our experience [J]. Seizure, 2004, 13(Suppl 1): S41-S48.
- 26. 中華醫學會神經病學分會. 新診斷癲癇初始抗癲癇發作藥物治療指南[J]. 中華神經科雜志, 2025, 58(11): 1137-1151.Chinese Society of Neurology, Chinese Medical Association. Guidelines for initial anti-seizure medication therapy in newly diagnosed epilepsy[J]. Chinese Journal of Neurology, 2025, 58(11): 1137-1151.
- 27. Baulac M, Brodie MJ, Patten A, et al. Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, non-inferiority trial[J]. The Lancet Neurology, 2012, 11(7): 579-588.
- 28. Ohtahara S. Zonisamide in the management of epilepsy-Japanese experience [J]. Epilepsy Research, 2006, 68(Suppl 2): S25-S33.
- 29. 中華醫學會兒科學分會神經學組. 新診斷兒童癲癇的初始單藥治療專家共識[J]. 中華兒科雜志, 2015, 53(10): 734-737.Neurology Group, Chinese Society of Pediatrics, Chinese Medical Association. Expert consensus on initial monotherapy in newly diagnosed childhood epilepsy[J]. Chinese Journal of Pediatrics, 2015, 53(10): 734-737.
- 30. Liu P, Zhang L, Zeng Q, et al. Efficacy and safety of zonisamide addition in children with developmental epileptic encephalopathy/epileptic encephalopathy: a real-world study[J]. CNS Neuroscience & Therapeutics, 2026, 32(4): e70865.
- 31. Wang S, Sun H, Wang Z, et al. Adjunctive treatment for pediatric focal epilepsy: a systematic review[J]. European Journal of Clinical Pharmacology, 2025, 81(4): 507-523.
- 32. Guerrini R, Rosati A, Segieth J, et al. A randomized phase iii trial of adjunctive zonisamide in pediatric patients with partial epilepsy[J]. Epilepsia, 2013, 54(8): 1473-1480.
- 33. Guerrini R, Rosati A, Bradshaw K, et al. Adjunctive zonisamide therapy in the long-term treatment of children with partial epilepsy: results of an open-label extension study of a phase III, randomized, double-blind, placebo-controlled trial[J]. Epilepsia, 2014, 55(4): 568-578.
- 34. Marson A, Burnside G, Appleton R, et al. The SANAD ii study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial[J]. The Lancet, 2021, 397(10282): 1363-1374.
- 35. 住友制藥株式會社. 唑尼沙胺片/散說明書 [Z], 2025.Sumitomo Pharmaceuticals Co. , Ltd. Instructions for Zonisamide Tablets/Powder [Z], 2025.
- 36. 中國抗癲癇協會. 臨床診療指南: 2023修訂版. 癲癇病分冊 [M]. 北京: 人民衛生出版社, 2023.China Association Against Epilepsy. Clinical practice guidelines (2023 revised edition): volume of epilepsy [M]. Beijing: People's Medical Publishing House, 2023.
- 37. Biton V. Clinical pharmacology and mechanism of action of zonisamide[J]. Clinical Neuropharmacology, 2007, 30(4): 230-240.
- 38. Wilfong A, Schultz R. Zonisamide for absence seizures[J]. Epilepsy Research, 2005, 64(1-2): 31-34.
- 39. Seki T, Kumagai N, Maezawa M. Effects of zonisamide monotherapy in children with epilepsy [J]. Seizure, 2004, 13(Suppl 1): S26-32.
- 40. Kothare SV, Valencia I, Khurana DS, et al. Efficacy and tolerability of zonisamide in juvenile myoclonic epilepsy[J]. Epileptic Disorders, 2004, 6(4): 267-270.
- 41. Velizarova R, Crespel A, Genton P, et al. Zonisamide for refractory juvenile absence epilepsy[J]. Epilepsy Research, 2014, 108(7): 1263-1266.
- 42. 北京協和醫院罕見病多學科協作組, 中國罕見病聯盟. 氯巴占治療難治性癲癇專家共識[J]. 協和醫學雜志, 2022, 13(5): 768-782.Multidisciplinary Team for Rare Diseases, Peking Union Medical College Hospital; China Rare Disease League. Expert consensus on clobazam for the treatment of refractory epilepsy[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(5): 768-782.
- 43. 中國抗癲癇協會創新與轉化專委會. Lennox-gastaut綜合征診斷治療的中國專家共識[J]. 癲癇雜志, 2022, 8(3): 187-195.Special Committee on Innovation and Translation, China Association Against Epilepsy. Chinese expert consensus on the diagnosis and treatment of Lennox-Gastaut Syndrome[J]. Journal of Epilepsy, 2022, 8(3): 187-195.
- 44. You SJ, Kang HC, Kim HD, et al. Clinical efficacy of zonisamide in lennox-gastaut syndrome: korean multicentric experience[J]. Brain & Development, 2008, 30(4): 287-290.
- 45. Lee YJ, Kang HC, Seo JH, et al. Efficacy and tolerability of adjunctive therapy with zonisamide in childhood intractable epilepsy[J]. Brain & Development, 2010, 32(3): 208-212.
- 46. 中國抗癲癇協會創新與轉化專業委員會, 中華醫學會兒科學分會罕見病學組, 中華醫學會兒科學分會神經學組. Dravet綜合征診斷與治療的中國專家共識[J]. 癲癇雜志, 2024, 10(1): 356-365.Special Committee on Innovation and Translation, China Association Against Epilepsy; Rare Diseases Group, Chinese Society of Pediatrics, Chinese Medical Association; Neurology Group, Chinese Society of Pediatrics, Chinese Medical Association. Chinese expert consensus on the diagnosis and treatment of Dravet Syndrome[J]. Journal of Epilepsy, 2024, 10(1): 356-365.
- 47. Wirrell EC, Laux L, Donner E, et al. Optimizing the diagnosis and management of dravet syndrome: recommendations from a north American consensus panel[J]. Pediatric Neurology, 2017, 68: 18-34.
- 48. Tanabe T, Awaya Y, Matsuishi T, et al. Management of and prophylaxis against status epilepticus in children with severe myoclonic epilepsy in infancy (SMEI; dravet syndrome)--a nationwide questionnaire survey in Japan [J]. Brain & Development, 2008, 30(10): 629-635.
- 49. Zuberi SM, Wirrell E, Yozawitz E, et al. ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: position statement by the ILAE task force on nosology and definitions[J]. Epilepsia, 2022, 63(6): 1349-1397.
- 50. Sharma S, Kaushik JS, Srivastava K, et al. Association of child neurology (AOCN) - indian epilepsy society (IES) consensus guidelines for the diagnosis and management of west syndrome[J]. Indian Pediatrics, 2021, 58(1): 54-66.
- 51. Ramantani G, Bolsterli BK, Alber M, et al. Treatment of infantile spasm syndrome: update from the interdisciplinary guideline committee coordinated by the german-speaking society of neuropediatrics[J]. Neuropediatrics, 2022, 53(6): 389-401.
- 52. Aslan M, Gungor S. Effectiveness of zonisamide in childhood refractory epilepsy[J]. Child's Nervous System, 2022, 38(5): 971-976.
- 53. Melikishvili G, Epitashvili N, Tabatadze N, et al. New insights in phenomenology and treatment of epilepsy in CDKL5 encephalopathy[J]. Epilepsy & Behavior, 2019, 94: 308-311.
- 54. Muller A, Helbig I, Jansen C, et al. Retrospective evaluation of low long-term efficacy of antiepileptic drugs and ketogenic diet in 39 patients with CDKL5-related epilepsy[J]. European Journal of Paediatric Neurology, 2016, 20(1): 147-151.
- 55. Ren Y, Hu W, Su S, et al. Recent advances of epilepsy associated with neurofibromatosis type 1[J]. Frontiers in Neurology, 2025, 16: 1640309.
- 56. Fanella M, Morano A, Cerulli Irelli E, et al. Idiopathic generalized epilepsy and café-au-lait macules as the predominant features in NF1 mild form[J]. Journal of Translational Genetics and Genomics, 2021, 5: 124-129.
- 57. Crino A, Fintini D, Bocchini S, et al. Obesity management in prader-willi syndrome: current perspectives[J]. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2018, 11: 579-593.
- 58. McElroy SL, Kotwal R, Guerdjikova AI, et al. Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial[J]. Journal of Clinical Psychiatry, 2006, 67(12): 1897-1906.
- 59. Gadde KM, Kopping MF, Wagner HR, et al. Zonisamide for weight reduction in obese adults: a 1-year randomized controlled trial[J]. Archives of Internal Medicine, 2012, 172(20): 1557-1564.
- 60. Whittington J, Holland A. A review of psychiatric conceptions of mental and behavioural disorders in prader-willi syndrome[J]. Neuroscience & Biobehavioral Reviews, 2018, 95: 396-405.
- 61. Yang LP, Perry CM. Zonisamide: in parkinson's disease[J]. CNS Drugs, 2009, 23(8): 703-711.
- 62. Matsunaga S, Kishi T, Iwata N. Combination therapy with zonisamide and antiparkinson drugs for parkinson's disease: a meta-analysis[J]. Journal of Alzheimer's Disease, 2017, 56(4): 1229-1239.
- 63. Aboulatta L, Haidar L, Abou-Setta A, et al. Efficacy and safety of MAO-B inhibitors safinamide and zonisamide in parkinson's disease: a systematic review and meta-analysis of randomized controlled trials[J]. CNS Drugs, 2023, 37(11): 941-956.
- 64. Essam M, Hamid E, Abushady E, et al. Role of zonisamide in advanced parkinson's disease: a randomized placebo-controlled study[J]. Neurological Sciences, 2024, 45(4): 1725-1734.
- 65. Chu CS, Yang FC, Tseng PT, et al. Treatment efficacy and acceptability of pharmacotherapies for dementia with lewy bodies: a systematic review and network meta-analysis[J]. Archives of Gerontology and Geriatrics, 2021, 96: 104474.
- 66. Odawara T, Hasegawa K, Kajiwara R, et al. Long-term efficacy and safety of zonisamide for treatment of parkinsonism in patients with dementia with lewy bodies: an open-label extension of a phase three randomized controlled tria [J]l. The American Journal of Geriatric Psychiatry, 2022, 30(3): 314-328.
- 67. Hasegawa K, Kochi K, Maruyama H, et al. Efficacy and safety of zonisamide in dementia with lewy bodies patients with parkinsonism: a post hoc analysis of two randomized, double-blind, placebo-controlled trials[J]. Journal of Alzheimer's Disease, 2021, 79(2): 627-637.
- 68. Zesiewicz TA, Ward CL, Hauser RA, et al. A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor[J]. Movement Disorders, 2007, 22(2): 279-282.
- 69. Morita S, Miwa H, Kondo T. Effect of zonisamide on essential tremor: a pilot crossover study in comparison with arotinolol[J]. Parkinsonism & Related Disorders, 2005, 11(2): 101-103.
- 70. Ondo WG. Zonisamide for essential tremor[J]. Clinical Neuropharmacology, 2007, 30(6): 345-349.
- 71. Pan XF, Fang ZZ, Zhang L, et al. Obesity in china: current progress and future prospects[J]. The Lancet Diabetes & Endocrinology, 2026, 14(2): 178-186.
- 72. Ben-Menachem E. Weight issues for people with epilepsy--a review [J]. Epilepsia, 2007, 48(Suppl 9): 42-45.
- 73. Ottman R, Lipton RB. Comorbidity of migraine and epilepsy[J]. Neurology, 1994, 44(11): 2105-2110.
- 74. Pappagallo M. Newer antiepileptic drugs: possible uses in the treatment of neuropathic pain and migraine[J]. Clinical Therapeutics, 2003, 25(10): 2506-2538.
- 75. Kochak GM, Page JG, Buchanan RA, et al. Steady-state pharmacokinetics of zonisamide, an antiepileptic agent for treatment of refractory complex partial seizures[J]. Journal of Clinical Pharmacology, 1998, 38(2): 166-171.
- 76. Mohammadianinejad SE, Abbasi V, Sajedi SA, et al. Zonisamide versus topiramate in migraine prophylaxis: a double-blind randomized clinical trial[J]. Clinical Neuropharmacology, 2011, 34(4): 174-177.
- 77. Villani V, Ciuffoli A, Prosperini L, et al. Zonisamide for migraine prophylaxis in topiramate-intolerant patients: an observational study[J]. Headache, 2011, 51(2): 287-291.
- 78. 中國抗癲癇協會共患病專業委員會. 癲癇共患偏頭痛診斷治療的中國專家共識[J]. 癲癇雜志, 2019, 5(5): 327-332.Special Committee on Comorbidities, China Association Against Epilepsy. Chinese expert consensus on diagnosis and treatment of epilepsy comorbid with migraine[J]. Journal of Epilepsy, 2019, 5(5): 327-332.
- 79. Berry-Noronha A, Manoleehakul P, Rottler A, et al. Risk of adverse pregnancy outcomes associated with antiseizure medications and their indications: a systematic review and meta-analysis[J]. Neurology, 2025, 104(3): e210233.
- 80. Weston J, Bromley R, Jackson CF, et al. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child[J]. Cochrane Database of Systematic Reviews, 2016, 11: CD010224.
- 81. Straub L, Hernandez-Diaz S, Bateman BT, et al. Prenatal antiseizure drug exposure and risk of neurodevelopmental disorders in children: population based cohort study[J]. British Medical Journal, 2026, 392: e085725.
- 82. Cross JH, Auvin S, Patten A, et al. Safety and tolerability of zonisamide in paediatric patients with epilepsy[J]. European Journal of Paediatric Neurology, 2014, 18(6): 747-758.
- 83. Low PA, James S, Peschel T, et al. Zonisamide and associated oligohidrosis and hyperthermia[J]. Epilepsy Research, 2004, 62(1): 27-34.
- 84. Knudsen JF, Thambi LR, Kapcala LP, et al. Oligohydrosis and fever in pediatric patients treated with zonisamide[J]. Pediatric Neurology, 2003, 28(3): 184-189.
- 85. Horiuchi K, Kudo A, Nakamura S, et al. Switching from zonisamide to perampanel improved the frequency of seizures caused by hyperthermia in dravet syndrome: a case report[J]. Journal of Medical Case Reports, 2024, 18(1): 3.
- 86. Elan Pharmaceuticals. Zonegran (zonisamide) package insert [Z], 2009.
- 87. Mula M. Topiramate and cognitive impairment: evidence and clinical implications[J]. Therapeutic Advances in Drug Safety, 2012, 3(6): 279-289.
- 88. Wandschneider B, Burdett J, Townsend L, et al. Effect of topiramate and zonisamide on fMRI cognitive networks[J]. Neurology, 2017, 88(12): 1165-1171.
- 89. Eun SH, Kim HD, Eun BL, et al. Comparative trial of low- and high-dose zonisamide as monotherapy for childhood epilepsy[J]. Seizure, 2011, 20(7): 558-563.
- 90. Park SP, Hwang YH, Lee HW, et al. Long-term cognitive and mood effects of zonisamide monotherapy in epilepsy patients[J]. Epilepsy & Behavior, 2008, 12(1): 102-108.
- 91. Dauphinais D, Knable M, Rosenthal J, et al. Zonisamide for bipolar depression: a randomized, double blind, placebo-controlled, adjunctive trial[J]. Psychopharmacology Bulletin, 2011, 44(2): 73-84.
- 92. Anand A, Bukhari L, Jennings SA, et al. A preliminary open-label study of zonisamide treatment for bipolar depression in 10 patients[J]. Journal of Clinical Psychiatry, 2005, 66(2): 195-198.
- 93. McElroy SL, Suppes T, Keck PE, et al. Open-label adjunctive zonisamide in the treatment of bipolar disorders: a prospective trial[J]. Journal of Clinical Psychiatry, 2005, 66(5): 617-624.
- 94. Cavanna AE, Seri S. Psychiatric adverse effects of zonisamide in patients with epilepsy and mental disorder comorbidities[J]. Epilepsy & Behavior, 2013, 29(2): 281-284.
- 95. Wu CB, Yao PS, Su LC, et al. Two cases of psychiatric symptoms associated with zonisamide antiepileptic treatment[J]. Clinical Psychopharmacology and Neuroscience, 2026, 24(1): 202-206.
- 96. Boycott KM, Rath A, Chong JX, et al. International cooperation to enable the diagnosis of all rare genetic diseases[J]. American Journal of Human Genetics, 2017, 100(5): 695-705.
- 97. Wroe S. Zonisamide and renal calculi in patients with epilepsy: how big an issue? [J] Current Medical Research and Opinion, 2007, 23(8): 1765-1773.
-
Previous Article
癲癇中心分級標準（2026版） -
Next Article
Risk factors for status epilepticus: a systematic review and meta-analysis